Siren, one of the most experienced agencies in the rare-disease space, will add its patient-outreach expertise to new owner Dohmen’s patient-care model.
Merck said in November that a long-running clinical trial finally demonstrated the impact of its Zetia cholesterol-lowering treatment on cardiovascular outcomes. The results from the so-called IMPROVE-IT trial are expected to shore up Zetia/Vytorin sales, analysts said, after the first trial showing that a non-statin added to a statin reduces cardiovascular events. Doctors now may…
Five things for pharma marketers to know: Wednesday, December 31
Pop songs about doctors get heavy rotation in BMJ; digital-health investment tally shows doubling in 2014; scientists finger bats as possible Ebola source.
Novo seeks to make Saxenda a familiar name in weight loss
The company is set to introduce its newest brand, Saxenda, into the crowded prescription obesity market as a higher-dose form of liraglutide than diabetes shot Victoza.
Five things for pharma marketers to know: Tuesday, December 30
NIH project for genome sequencing of newborns commences; remote care, next-gen. DNA sequencing top list of 2014 healthcare-market trends; WHO plans evaluation of contagious-disease response.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix